International Conference on Oncology and Biomarkers
ICOOAB
Official Invitation Letter Available
An official invitation letter will be provided upon successful registration for your participation in the conference.
Benefits of Registering as Listener
Access to All Conference Sessions
Plenary, keynote and parallel sessions
Networking Opportunities
Connect with global educators & researchers
Certificate of Participation
Digital certificate of participation
Invitation Letter Support
Official invitation letter after successful registration
Conference Kit / Digital Materials
E-proceedings & resource materials
Access to Keynote Sessions
Learn from leading experts & scholars
Conference Session Tracks
Aligned with UN Sustainable Development Goals
The conference's session tracks effectively support the following SDGs.
This track will explore the latest innovations in the development of anticancer drugs, focusing on novel compounds and therapeutic strategies. Participants will discuss the challenges and successes in translating preclinical findings into clinical applications.
SDG 3
SDG 4
This session will delve into the methodologies and technologies employed in the discovery and validation of cancer biomarkers. Emphasis will be placed on the role of biomarkers in early detection, prognosis, and treatment response.
SDG 3
SDG 9
This track will highlight the application of bioinformatics tools and techniques in understanding cancer biology and treatment outcomes. Researchers will present case studies demonstrating how data analysis can drive insights into cancer mechanisms.
SDG 3
SDG 9
This session will focus on the design, implementation, and outcomes of clinical trials in oncology. Discussions will include regulatory considerations, patient recruitment strategies, and the impact of trial results on clinical practice.
SDG 3
SDG 4
This track will examine the genetic and epigenetic factors contributing to cancer development and progression. Participants will discuss the implications of genetic research for personalized medicine and targeted therapies.
SDG 3
SDG 9
This session will cover the latest advancements in molecular diagnostic technologies for cancer detection and monitoring. The focus will be on integrating these technologies into routine clinical practice to improve patient outcomes.
SDG 3
SDG 4
This track will explore the evolving landscape of immunotherapy in oncology, including checkpoint inhibitors and CAR T-cell therapy. Experts will discuss clinical experiences, challenges, and future prospects in harnessing the immune system against cancer.
SDG 3
SDG 4
This session will address the epidemiological aspects of cancer, including risk factors, prevention strategies, and public health initiatives. Participants will share insights on how epidemiological research informs cancer prevention efforts.
SDG 3
SDG 4
This track will focus on the latest research and clinical advancements in the management of gastrointestinal cancers. Discussions will include novel therapeutic approaches and the role of biomarkers in treatment selection.
SDG 3
SDG 4
This session will cover the latest findings in the research and treatment of hematological malignancies, including leukemias and lymphomas. Participants will discuss emerging therapies and the importance of personalized treatment strategies.
SDG 3
SDG 4
This track will emphasize the importance of translational research in bridging the gap between laboratory discoveries and clinical applications in oncology. Experts will share successful case studies that illustrate effective collaboration between researchers and clinicians.
SDG 3
SDG 4